Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETI-tacrolimus drug-drug interaction study in adults with cystic fibrosis after transplantation
2020-005224-12Phase 4Active
- Sponsor
- HagaZiekenhuis
- Start
- Jan 2021
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of elexacaftor, tezacaftor, ivacaftor and tacrolimus in cystic fibrosis (CF), sponsored by HagaZiekenhuis. Primary endpoints: Tacrolimus pharmacokinetic interaction and Change in tacrolimus PK parameters. Started Jan 2021; status: active.
02
Drugs
elexacaftortezacaftorivacaftortacrolimus
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2020-005224-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005224-12.